Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
G1T28 (trilaciclib) is an IV-administered transient CDK 4/6 inhibitor, which is being evaluated in combination with gemcitabine & carboplatin for the treatment of metastatic triple negative breast cancer.
Lead Product(s): Trilaciclib,Gemcitabine,Carboplatin
Therapeutic Area: Oncology Product Name: Cosela
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 12, 2024
Details:
Cosela (Trilaciclib hydrochloride), an IV-administered transient CDK4/6 inhibitor, is a first-in-class therapy designed to preserve bone marrow and immune system function during chemotherapy to improve patient outcomes.
Lead Product(s): Trilaciclib,Gemcitabine,Carboplatin
Therapeutic Area: Oncology Product Name: Cosela
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 03, 2023
Details:
The data highlight the potential for G1T28 (trilaciclib) to meaningfully reduce adverse events related to use of sacituzumab. As expected, patients with PD-L1(+) tumors appear to respond earlier than patients with PD-L1(-) tumors.
Lead Product(s): Trilaciclib,Sacituzumab Govitecan
Therapeutic Area: Oncology Product Name: Cosela
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 10, 2023
Details:
Cosela (Trilaciclib) is a CDK4 and CDK6 inhibitor, indicated to reduce the incidence of chemotherapy induced myelosuppression in patients before topotecan-containing or platinum and etoposide-containing chemotherapy for extensive stage small cell lung cancer.
Lead Product(s): Trilaciclib,Bevacizumab,Fluorouracil
Therapeutic Area: Oncology Product Name: Cosela
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 13, 2023
Details:
Cosela (Trilaciclib) is a CDK4 and CDK6 inhibitor, indicated to reduce the incidence of chemotherapy induced myelosuppression in patients before topotecan-containing or platinum and etoposide-containing chemotherapy for extensive stage small cell lung cancer.
Lead Product(s): Trilaciclib,Bevacizumab
Therapeutic Area: Oncology Product Name: Cosela
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 09, 2023
Details:
Cosela (Trilaciclib hydrochloride), an IV-administered transient CDK4/6 inhibitor, is a first-in-class therapy designed to preserve bone marrow and immune system function during chemotherapy to improve patient outcomes.
Lead Product(s): Trilaciclib,Gemcitabine,Cisplatin
Therapeutic Area: Oncology Product Name: Cosela
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 04, 2023
Details:
The results show that trilaciclib monotherapy can improve the ratio of CD8+ T cells to Tregs and thus may enhance the overall antitumor immune response and confirm the trends we observed in preclinical studies and in peripheral blood in our Phase 2 trial in TNBC.
Lead Product(s): Trilaciclib,Doxorubicin Hydrochloride,Cyclophosphamide
Therapeutic Area: Oncology Product Name: Cosela
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2022
Details:
Company intends to use the net proceeds from this offering for working capital and general corporate purposes, including development of Cosela, having trilaciclib hydrochloride.
Lead Product(s): Trilaciclib
Therapeutic Area: Oncology Product Name: Cosela
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cowen
Deal Size: $50.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 22, 2022
Details:
Company intends to use the net proceeds from this offering for working capital and general corporate purposes, including development of Cosela, having trilaciclib hydrochloride.
Lead Product(s): Trilaciclib
Therapeutic Area: Oncology Product Name: Cosela
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cowen
Deal Size: $50.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 17, 2022
Details:
Trilaciclib (Cosela), is well tolerated when administered prior to sacituzumab. Initial data on the first 18 patients show a effect of trilaciclib to reduce (>50%) the rates of multiple adverse events compared to the sacituzumab govitecan-hziy single agent safety profile.
Lead Product(s): Trilaciclib,Sacituzumab Govitecan
Therapeutic Area: Oncology Product Name: Cosela
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2022